Insider Selling: Heartflow (NASDAQ:HTFL) Director Sells $218,560.00 in Stock

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 8,000 shares of Heartflow stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total value of $218,560.00. Following the completion of the transaction, the director owned 36,413 shares of the company’s stock, valued at approximately $994,803.16. This trade represents a 18.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Heartflow Stock Down 1.3%

HTFL stock opened at $26.95 on Thursday. The firm has a 50-day moving average of $30.24. The firm has a market cap of $2.30 billion and a price-to-earnings ratio of -14.89. Heartflow, Inc. has a 1 year low of $25.36 and a 1 year high of $41.22.

Institutional Investors Weigh In On Heartflow

A number of institutional investors and hedge funds have recently made changes to their positions in HTFL. TFC Financial Management Inc. acquired a new position in shares of Heartflow in the third quarter valued at approximately $40,000. Legal & General Group Plc purchased a new position in Heartflow in the 3rd quarter valued at $59,000. Strs Ohio acquired a new position in Heartflow in the 4th quarter valued at $99,000. Y Intercept Hong Kong Ltd purchased a new position in Heartflow during the 3rd quarter worth $234,000. Finally, Staley Capital Advisers Inc. acquired a new stake in shares of Heartflow in the 4th quarter worth $204,000.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Brokerages have raised price targets and added coverage (Wells Fargo started coverage with an “overweight”; JPMorgan, Stifel and Canaccord have lifted targets near $38–$40), which supports medium‑term upside expectations.
• Neutral Sentiment: Small institutional buys have shown modest inflows from several funds in recent quarters — a limited vote of confidence but not large enough to counter recent selling.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at about $27.46 (~$619.6k), trimming his stake — insider selling by the CEO can sap near‑term sentiment and supply. Insider Selling: CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), cutting her holding ~18% — additional insider sales amplify negative optics. Director Sale
• Negative Sentiment: Short interest surged in late January to ~4.95M shares (up ~42% vs. mid‑January), representing roughly 5.8% of float and a ~5.9 days‑to‑cover — higher short positioning can amplify downside on negative news and increases selling pressure.
• Negative Sentiment: Reports of a large shareholder sell‑off (headline coverage cited a multi‑million dollar block sale) likely added supply and weighed on the stock. Major Shareholder Sale

Wall Street Analyst Weigh In

Several research firms have commented on HTFL. JPMorgan Chase & Co. boosted their price target on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Stifel Nicolaus increased their target price on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company began coverage on Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, Canaccord Genuity Group boosted their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.